The tweet was deleted by the author.
But we saved everything 🙂.
Cencora presented views on the benefits of incorporating real world evidence and data early into a product's lifecycle at Asembia AXS26. The remarks came from Tommy Bramley during a session recorded live for Pharmaceutical Commerce.
Cencora shared a link to the recorded conversation on social media. Details are available in the full video.
COR (Cencora) is trading at $271.83, below the MA-20 ($273.18), MA-50 ($285.78), and MA-200 ($324.84), highlighting sustained downside pressure across all major timeframes. The Ichimoku Kijun at $268.56 is slightly below the current price, marking immediate support, while near-term resistance appears at MA-20 ($273.18) and key resistance at MA-50 ($285.78); support is clustered at the Ichimoku Kijun ($268.56) for near-term and at MA-100 ($316.45) as key support.
Momentum indicators on D1 confirm a bearish environment, with MACD showing a strong sell and ADX (33.54) signaling a robust downward trend. RSI (43.40) remains weak, with Stoch RSI and CCI both neutral, indicating the market is not yet oversold; BBP points to an overbought condition, suggesting sellers are dominating. AO is neutral and does not provide further confirmation. COR has fallen $9.84 (3.49%) from last week's close of $281.67, positioning the price at the very bottom of the current weekly range and highlighting persistent weakness as weekly volatility stands at 5.00%. In today's session, the stock is down 1.90%, deepening its decline from recent highs and reflecting renewed selling pressure.
Looking ahead to the next week, a realistic forecast range for COR is $267 to $278, keeping within ±4% of the current price and in line with recent volatility. This range remains well above the 52-week low ($244.82) and far below the 52-week high ($377.54), underscoring the prevailing downward shift. Short-term signals on both D1 and W1 frames (RSI, MACD, ADX, MA-50) are uniformly bearish, resulting in a very high probability (more than 80%) of further declines and only a very low probability (less than 20%) of a recovery. Baseline scenario: prices remain rangebound between $267 and $278 as consolidation develops. A bullish breakout above $278 could open the way toward the $285–$287 resistance cluster. If bearish pressure intensifies and support at $267 fails, the next downdraft could test the $262–$265 area.
Earlier, analysts noted that One Alliance North America Insurance Company maintained its BBB financial strength rating as it repositions its business following an ownership change and rebranding. For Cencora, the prevailing scenario warrants attention to how evolving sector dynamics may present both risks and opportunities, with a key level to watch as the company navigates the next quarter.